Resumo

PEREIRA, Ana S.; XARA, Joana; FLOR, Duarte  e  GONCALO, Margarida. Omalizumab and new therapeutic targets in chronic spontaneous urticaria. Port J Dermatol Venereol. [online]. 2024, vol.82, n.1, pp.11-22.  Epub 06-Mar-2024. ISSN 2795-501X.  https://doi.org/10.24875/pjdv.24000013.

Chronic spontaneous urticaria (CSU) is a common and distressing skin disease characterized by itchy wheals, angioedema, or both. There is currently no cure for CSU and symptomatic treatment is often insufficient. Omalizumab, a humanized anti-immunoglobulin (Ig) E monoclonal antibody, remains the only biological drug licensed for CSU, almost a decade after its approval. However, growing knowledge of the pathophysiological mechanisms of this disease has led to recent advances in its treatment, with several drugs in investigation both in pre-clinical and clinical settings. These include biologicals, such as dupilumab (anti-IL-4Rα), secukinumab (anti-IL-17), tezepelumab (anti-TSLP), ligelizumab (anti-IgE), lirentelumab (anti-Siglet 8), and barzovolimab (anti-cKIT), as well as “small molecules,” such as Bruton tyrosine kinase (BTK) inhibitors (remibrutinib) and a Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist. Here, we review the current and future therapeutic options for CSU, based on what is known about the pathogenesis of the disease.

Palavras-chave : Chronic spontaneous urticarial; Mast cells; Omalizumab; Novel biologics; Small molecules.

        · resumo em Português     · texto em Inglês     · Inglês ( pdf )